These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2797645)

  • 21. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
    Rose WC
    J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
    Li LH; DeKoning TF; Wallace TL
    Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
    Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.
    Ghamande S; Hylander BL; Oflazoglu E; Lele S; Fanslow W; Repasky EA
    Cancer Res; 2001 Oct; 61(20):7556-62. PubMed ID: 11606394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
    Sirotnak FM; Schmid FA; DeGraw JI
    Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
    Wampler GL; Carter WH; Campbell ED; Goldman ID
    Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo.
    Yu NY; Patawaran MB; Chen JY; Orenberg EK; Brown DM; Luck EE
    Cancer J Sci Am; 1995; 1(3):215-21. PubMed ID: 9166479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL; Zou WY; Song LH; Wei W
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemo-immunotherapeutical studies on Dalton's lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro.
    Sarna S; Bhola RK
    Arch Immunol Ther Exp (Warsz); 1993; 41(5-6):327-33. PubMed ID: 8010874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Campora E; Bruzzone M; Chiara S; Alama A; Iskra L; Carnino F; Parodi S; Foglia G; Ragni N; Rosso R
    Gynecol Oncol; 1990 Apr; 37(1):39-43. PubMed ID: 2323610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of combinations of interferons and cytotoxic drugs in murine tumor models in vivo.
    Harrison SD; Stevens JJ; Waud WR; Dykes DJ; Schmid SM; Griswold DP
    J Biol Response Mod; 1990 Aug; 9(4):395-400. PubMed ID: 2118561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.